Drug Information

Drug General Information
Drug ID
D07WCT
Former ID
DIB011175
Drug Name
SAR-100842
Synonyms
LPA1/LPA3 antagonist (renal fibrosis), sanofi-aventis
Indication Fibrosis [ICD9: 709.2; ICD10:L90.5] Phase 2 [523991]
Company
Sanofi us
Target and Pathway
Target(s) Lysophosphatidic acid receptor Edg-2 Target Info Modulator [544454]
Lysophosphatidate-3 receptor Target Info Modulator [544454]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
PI3K-Akt signaling pathway
Gap junction
Pathways in cancerhsa04015:Rap1 signaling pathway
Pathways in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database LPA receptor mediated eventslysophospholipid_pathway:LPA receptor mediated events
Reactome G alpha (q) signalling events
G alpha (i) signalling events
Lysosphingolipid and LPA receptorsR-HSA-416476:G alpha (q) signalling events
Lysosphingolipid and LPA receptors
WikiPathways Myometrial Relaxation and Contraction Pathways
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signalingWP2664:Gastrin-CREB signalling pathway via PKC and MAPK
GPCR downstream signaling
References
Ref 523991ClinicalTrials.gov (NCT01651143) Proof of Biological Activity of SAR100842 in Systemic Sclerosis. U.S. National Institutes of Health.
Ref 544454Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.